Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data

Source:  Hillstream Biopharma, Inc. 4/10/2023

In IND-enabling studies, HSB-1216 remained tightly bound within the Quatramer™ until reaching its tumor target, consistent with earlier pre-clinical studies demonstrating reduction of tumor growth

Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing a portfolio of therapeutic candidates targeting drug resistant and devastating cancers, announced pharmacokinetic (PK) data of HSB-1216 supportive of its development strategy and pre-clinical data. These data suggest Quatramer protects HSB-1216 from metabolic degradation until its release at the tumor site and is consistent with the promising efficacy data demonstrating effective reduction of tumor growth in pre-clinical studies.

The preliminary safety and PK of HSB-1216 was evaluated in IND-enabling studies using rats and dogs showing the Quatramer bound HSB-1216 throughout a 48-hour exposure period prevented degradation in the in systemic circulation until its targeted release at the tumor site.

“We are greatly encouraged by these early PK data which are both supportive of our overall development strategy as well as our earlier pre-clinical data,” said Randy Milby, Hillstream’s Chief Executive Officer.

About Hillstream BioPharma Inc.
Hillstream BioPharma, Inc. is a biotechnology company developing a portfolio of therapeutic candidates targeting drug resistant and devastating cancers. The Company anticipates submitting an investigational new drug application in the second half of 2023 with HSB-1216, which targets ferroptosis, an emerging new anti-cancer mechanism, resulting in iron mediated cell death (IMCD) of drug resistant cancers. The Company’s emerging immuno-oncology pipeline is led by HSB-3215, a novel anti-HER2 monoclonal antibody targeting unique epitopes with a novel mechanism of action. The erbB/HER family of cell surface proteins include well-known and validated drug targets including HER2 and HER3 found in multiple solid tumors, including breast, lung, GYN, endocrine and CNS.